8月12日 - ** 生物技术公司Humacyte（HUMA.O）股价下跌10%，至63美分
** 该公司公布第二季度每股亏损16美分，亏损幅度大于分析师预估的每股亏损1美分——LSEG数据
** 报告显示第二季度营收为40.6万美元，低于112万美元的预期
** BTIG表示：“我们仍然认为，随着里程碑的达成和商业化进程的推进，股价有望走高，但承认短期内营收的可预测性仍然有限。”
** HUMA报告称，截至6月30日，其现金、现金等价物及受限现金为8,030万美元
** 截至上一交易日收盘，该股年内累计跌幅达35.3%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.